- Affiliate Assistant Professor, Global Health
- VP, Formulations
Select from the following:
Dr. Christopher Fox is the Vice President of Formulations at the Infectious Disease Research Institute (IDRI) and oversees the research and development of vaccine adjuvants. With over 18 years of product development experience in adjuvants and formulations including cGMP manufacture and clinical testing, and over 100 publications, Dr. Fox has established himself as an expert in this field. He is the editor of a volume from the Springer Methods in Molecular Biology Series entitled “Vaccine Adjuvants: Methods and Protocols” published in 2017 and has served as the principal investigator of multiple grants and contracts from US government agencies and foundations. He has also directed technology transfer of adjuvant formulation manufacturing to institutes in India, Brazil, South Africa, and Romania. Dr. Fox was awarded the 2015 Pioneers in Global Health Rising Leader Award from the Washington Global Health Alliance.
- PhD (University of Utah)
- BS (Utah State University)
- English
- Spanish
- Bioengineering
- Diarrheal Diseases
- Drug and Vaccine Development
- Immunizations
- Influenza
- Innate Immunity
- Neglected Diseases, Tropical Medicine (incl. Parasites)
- Pharmaceutical Science
- TB
- Zoonotic Diseases and Animal Health
- Advanced development and clinical evaluation of a synthetic intranasal Entamoeba histolytica vaccine containing adjuvant
- Development and Clinical Evaluation of a Lyophilized Thermostable Tuberculosis Vaccine containing Adjuvant
- Engineering Sustainable Squalene Analogues for Novel Vaccine Adjuvant Emulsions
Abhyankar MM, Orr MT, Kinsey R, Sivananthan S, Nafziger AJ, Oakland DN, Young MK, Farr L, Uddin MJ, Leslie JL, Burgess SL, Liang H, De Lima I, Larson E, Guderian JA, Lin S, Kahn A, Ghosh P, Reed S, Tomai MA, Pedersen K, Petri WA Jr, Fox CB. “Optimizing a multi-component intranasal Entamoeba histolytica vaccine formulation using a design of experiments strategy,” Frontiers in Immunology, 2021, 12:683157.
Phan T, Devine C, Laursen ED, Simpson A, Kahn A, Khandhar AP, Mesite S, Besse B, Mabery KJ, Flanagan EI, Fox CB. “Squalene emulsion manufacturing process scale-up for enhanced global pandemic response,” Pharmaceuticals, 2020, 13:168.
Methods in Molecular Biology: Vaccine Adjuvants; Fox CB, Editor; Springer, New York, 2017.
Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG. “Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: a formulation approach,” Journal of Controlled Release, 2016, 244:98-107.
Reed SG, Orr MT, Fox CB. “Key roles of adjuvants in modern vaccines,” Nature Medicine, 2013, 19:1597-1608.